Gary Sunderland was recovering from a heart procedure at New Hanover Regional Medical Center when a physician assistant stopped by to assess him. Using a stethoscope, the physician assistant listened to the carotid artery in his neck.
She didn’t like what she heard.

He got a referral to a vascular surgeon and discovered he had blockages in his carotid arteries, which carry oxygenated blood to the brain. Carotid artery disease, which happens when plaque clogs the blood vessels, increases the risk of a stroke.
“It was like a ticking time bomb,” said Sunderland, who is 81 and has enjoyed good health all his life.

​The most commonly performed surgery to remedy blocked carotid arteries is a carotid endarterectomy, which involves a surgeon opening the artery to remove the plaque. This procedure is offered at NHRMC, but it is invasive and not ideal for everyone.

After reviewing Sunderland’s case, Dr. Michael Patton, a Wilmington vascular surgeon, recommended a minimally invasive procedure to place stents in his carotid arteries, lowering his risk of stroke. Patton placed the stents, which are small mesh tubes, using the TCAR procedure, which stands for transcarotid artery revascularization.

Read More: https://www.kinston.com/news/20190513/minimally-invasive-procedure-can-reduce-stroke-risk

Stealthy catheter developer Route 92 Medical, which is developing a catheter to treat stroke, last week said it raised nearly $13 million in an equity round.

Founded in 2015, San Mateo, Calif.-based Route 92 won 510(k) clearance from the FDA a year ago for a percutaneous catheter. The company holds U.S. patents for treating acute ischemic stroke, a rapid aspiration thrombectomy system and intra-cerebral implant delivery.

According to regulatory filings, Route 92 first drummed up $5.9 million in May 2016. Just less than a year later the company doubled that raise, adding another $4.7 million in August 2018. Including the most-recent May 25 filing, Route 92 Medical has raised $29.5 million in equity rounds.

Read More: https://www.massdevice.com/stealthy-route-92-medical-raises-13m/

SUNNYVALE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2019.

Recent Highlights

• Recorded revenues of $12.8 million for the first quarter of 2019, representing a 124% increase over the first quarter of 2018
• Completed initial public offering of six million shares, raising approximately $108.8 million in net proceeds, after deducting underwriting fees and other expenses
• Completed enrollment in the ROADSTER 2 study
• Clinical data from the TCAR Surveillance Project to be presented at the Society for Vascular Surgery’s Vascular Annual Meeting in June​​

​“At Silk Road Medical, we are motivated by relentless dedication to successful patient outcomes and by our focus on two key priorities of expanding the clinical evidence and U.S. commercial execution. We are pleased to report first quarter results which reflect these priorities,” said Erica Rogers, Chief Executive Officer. “Commercial momentum is achieved by driving physician adoption of TCAR procedures which recently surpassed 10,000 globally. We are simultaneously progressing forward with clinical evidence and are pleased to announce that we have completed enrollment in our ROADSTER 2 study.”

Read More: https://www.globenewswire.com/news-release/2019/05/08/1819696/0/en/Silk-Road-Medical-Reports-First-Quarter-2019-Financial-Results.html

Company’s Research Initiative Recognized as Novel, Innovative Approach to Deliver More Personalized Dialysis Treatment

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced that a project featuring the Tablo™ Hemodialysis System has been selected as a winner of the KidneyX Redesign Dialysis Competition. Outset’s winning concept seeks to couple data from Tablo’s unique set of sensors and automation capabilities with physiologic data from the patient to deliver personalized dialysis treatments, ultimately improving outcomes for patients.
​
The KidneyX Redesign Dialysis Competition is a partnership between the U.S. Department of Health and Human Services and the American Society of Nephrology to support innovative strategies for tackling kidney disease, a space that has been historically underfunded despite a growing patient population and poor patient outcomes, including high mortality and low quality of life. These sub-optimal outcomes are due in part to dialysis treatment decisions driven by incomplete, imprecise physiologic measurements and a one-size-fits-all approach to treatment planning. Tablo has a proprietary suite of sensors and data sets that can allow it to merge data from the machine and the patient in order to automatically adjust treatment parameters and customize therapy to an individual patient’s needs, all without interrupting clinic workflow.

Read More: https://www.businesswire.com/news/home/20190429005751/en/Outset-Medical-Announced-KidneyX-Award-Winner-U.S./?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT

The Centers for Disease Control and Prevention reports that nearly 800,000 people in the United States have suffered strokes. Stroke Awareness Month, which occurs in May, is quickly approaching, which makes this a good time to discuss the medical advances in this area. Thankfully, the medical field is rapidly advancing, and new techniques and procedures are created every year. Transcarotid artery revascularization (TCAR) is one such procedure that can change the lives of patients at risk for stroke.

Dr. R. Michael Patton of Wilmington Surgical Associates, located at 1414 Medical Center Drive, is one of the few in town who can perform TCAR, and has some information on this procedure.
​
1. TCAR is a very new procedure
TCAR is a very new surgical procedure for patients at high risk of stroke. Drs. Michael Patton and Thomas Eskew, vascular partners at Wilmington Surgical Associates, were the first surgeons in Eastern North Carolina to perform this procedure. It was performed at New Hanover Regional Medical Center for the first time in early 2018. New Hanover Regional Medical Center is also considered a TCAR Center of Excellence, and there are four surgeons who can perform this procedure in Wilmington.

Read More: https://www.thetimesnews.com/news/20190417/tcar-procedure-can-be-life-changing-for-patients-at-risk-of-stroke

Shares of Silk Road Medical (SILK) popped more than 80% on Thursday with an initial public offering that drew heavy interest from investors. The Silk Road Medical IPO raised $120 million.

Shares priced at 20, the high end of its estimated range, and opened at 33.15. The stock climbed further, closing at 36.18, up 80.9% on the stock market today. Silk Road initially set a price range of 15 to 17, later revised to a range of 19 to 20.

Silk Road also hiked the number of shares for the offering by 28% to 6 million.

The Silk Road IPO garnered lots of attention from investors, with one IPO research firm giving the company its highest rating.

Read More: https://www.investors.com/news/technology/silk-road-medical-ipo-initial-public-offering-2/?src=A00220&yptr=yahoo

SUNNYVALE, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq:SILK) (“Silk Road Medical”) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $20.00 per share. All of the shares of common stock are being offered by Silk Road Medical. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Silk Road Medical’s common stock is expected to begin trading on The Nasdaq Global Market on April 4, 2019, under the ticker symbol “SILK”. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Silk Road Medical, are expected to be approximately $120 million. Silk Road Medical will not receive any proceeds from the sale of shares of common stock by the selling stockholders if the underwriters exercise their option to purchase additional shares. The offering is expected to close on April 8, 2019, subject to the satisfaction of customary closing conditions.

Read More: https://www.globenewswire.com/news-release/2019/04/03/1796738/0/en/Silk-Road-Medical-Announces-Pricing-of-Initial-Public-Offering.html

Medical device company Silk Road Medical (SILK) priced its initial public offering at 20 a share, at the high end of its recently raised expected range. The Silk Road IPO garnered lots of attention from investors, with one IPO research firm giving the company its highest rating. Silk Road stock will start trading Thursday.

Silk Road Medical raised $120 million after selling six million shares. The Silk Road Medical IPO price range was recently raised to 19 to 20 per share from 15 to 17. Silk Road also hiked the number of shares on offer by 28% to 6 million from 4.7 million.

​"There is little question that this IPO is the 'deal of the week' and we have been told by the underwriters to manage expectations accordingly," IPOboutique.com said in a note to clients. The IPO research firm rates IPOs on a scale of 1 to 5. It gave Silk Road a rare rating of 5, or "strongest buy," at the IPO price. The last IPO that received a 5 rating was Facebook (FB) in 2012. Glitches marred the Facebook IPO, though.

Read More: https://www.investors.com/news/technology/silk-road-medical-ipo-initial-public-offering/

Silk Road Medical, which sells medical devices to treat carotid artery disease, announced terms for its IPO on Monday. 

The Sunnyvale, CA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. Insiders intend to purchase $15 million worth of shares in the offering (20% of the deal). At the midpoint of the proposed range, Silk Road Medical would command a fully diluted market value of $513 million. 

Silk Road Medical was founded in 2007 and booked $35 million in sales for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol SILK. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. It is expected to price during the week of April 1, 2019.

Read More: https://www.nasdaq.com/article/carotid-artery-device-maker-silk-road-medical-sets-terms-for-75-million-ipo-cm1119264

​Dive Brief:

• Omada Health has added FDA-cleared, cellular-connected blood pressure cuffs and glucose monitors to its chronic disease management program.
• Like rival Livongo, Omada seeks to improve health outcomes and lower costs for employers and health plans by giving people disease management tools and support.
• Omada's expansion of its technology portfolio comes seven months after Livongo unveiled its own cellular-connected blood pressure cuff.

​Read More: https://www.medtechdive.com/news/omada-adds-connected-blood-pressure-cuff-glucometer-to-health-program/550382/